دورية أكاديمية
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
| العنوان: | Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab |
|---|---|
| المؤلفون: | De Filippi R., Morabito F., Santoro A., Tripepi G., D'Alo F., Rigacci L., Ricci F., Morelli E., Zinzani P. L., Pinto A. |
| المساهمون: | De Filippi, R., Morabito, F., Santoro, A., Tripepi, G., D'Alo, F., Rigacci, L., Ricci, F., Morelli, E., Zinzani, P. L., Pinto, A. |
| سنة النشر: | 2021 |
| المجموعة: | IRIS Università degli Studi di Napoli Federico II |
| مصطلحات موضوعية: | Body mass index, Hodgkin lymphoma, Immune checkpoint inhibitor, Immune-related adverse event, Adolescent, Adult, Aged, 80 and over, Female, Human, Male, Middle Aged, Nivolumab, Programmed Cell Death 1 Receptor, Retrospective Studie, Young Adult, Antineoplastic Agents, Immunological, Hodgkin Disease |
| الوصف: | Background: Overweight and obese patients with solid tumors receiving anti-programmed cell death-1 (PD-1)/PD-ligand-1(PD-L1) immune checkpoint inhibitors exhibit improved survival and higher risk of immune-related adverse events (irAEs) than those with a normal body mass index (BMI). In classic Hodgkin lymphoma (cHL), the impact of BMI on survival and immune-related toxicity is unknown. We evaluated for the first time associations of BMI with survival and irAEs in patients with relapsed/refractory (RR)-cHL undergoing PD-1 blockade. Methods: Data from a multicenter study on 133 patients treated with the anti-PD1 antibody nivolumab (July 2015–December 2016) were retrieved from a prospective database. Progression-free (PFS), overall survival (OS), incidence and severity of irAEs according to BMI categories were estimated by Kaplan–Meier method, landmark-analyses and Cox regressions. Results: Patients, mostly males (63%, n = 84) with a median age of 35 years (range, 15–82), advanced stage (75%), B symptoms (63%), bulky disease (24%), a median of 4 previous treatments (range, 1–9), received a median of 18 nivolumab doses (range, 1–57). No statistically significant differences across BMI subgroups emerged as to PFS, with 1-year rates of 67.1% for both normal weight (n = 66; 49.6%) and overweight (n = 31; 23.3%) patients. Underweight (n = 12; 9%) and obese (n = 24; 18%) patients had a 1-year PFS of 54.5% and 49%, respectively. In survival analyses, BMI either as a continuous (P = 0.5) or categorical (P for trend = 0.63) variable failed to associate with PFS. Response rates and time-to-response did not cluster in any BMI subset. No BMI-related differences in OS emerged across normal, overweight and obese patients but underweight patients had the worst survival. Occurrence of irAEs of whatever severity did not statistically associate with BMI. Conclusions: In patients with RR-cHL receiving nivolumab, no statistically significant differences emerged in response rates, PFS and OS across BMI categories of normal weight, ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/wos/WOS:000724767600001; volume:19; issue:1; firstpage:489; journal:JOURNAL OF TRANSLATIONAL MEDICINE; http://hdl.handle.net/11588/867234Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85120318131 |
| DOI: | 10.1186/s12967-021-03134-4 |
| الإتاحة: | https://doi.org/10.1186/s12967-021-03134-4Test http://hdl.handle.net/11588/867234Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.D9886250 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1186/s12967-021-03134-4 |
|---|